Published January 12, 2024
| Version v1
Journal article
Open
Attitude of medical doctors to adverse drug reactions reporting in Bulgaria
Authors/Creators
- 1. Medical University Sofia, Sofia, Bulgaria
Description
Adverse Drug Reactions (ADRs) pose a challenge for medical doctors (MDs) and other healthcare professionals (HCPs). Serious ADRs increase patient morbidity and mortality and generate a large financial footprint on healthcare costs.
Statistics show that about 6% of hospitalizations are due to ADRs and over 50% of them could be avoided. Two years after introducing the pharmacovigilance (PhV) requirements in the European Union, national regulatory PhV requirements were published in the Bulgarian pharmaceutical legislation. Nonetheless, MDs' awareness of the PhV topic still remains extremely important due to patient safety.
Spontaneous reporting of ADRs is essential to the success of a pharmacovigilance program. Underreporting of ADRs is common, especially among MDs and HCPs.
This study aims to analyse the attitude and the knowledge of graduated MDs towards the reporting of ADRs and drug safety in general. In addition, the study aims to examine their opinion, attitude, and recommendations so that reporting of ADRs becomes more regular.
Files
PHAR_article_115559.pdf
Files
(605.9 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:f514f1164681bc121fdb15195310c600
|
538.9 kB | Preview Download |
|
md5:7b7f2ed57a73fbab58e8fad202ef1900
|
67.1 kB | Preview Download |
Additional details
References
- Abubakar AR, Simbak NB, Haque M (2014) A systematic review of knowledge, attitude and practice on adverse drug reactions and pharmacovigilance among doctors. Journal of Applied Pharmaceutical Science 4: 117–127. https://doi.org/10.7324/JAPS.2014.401021
- Bahri P, Harrison-Woolrych M (2012) Focusing on risk communication about medicines: why now? Drug Safety 35(11): 971–975. https://doi.org/10.1007/BF03261984
- Benisheva-Dimitrova T, Trendafilova P, Petkova V, Sidjimova D, Naseva E (2014) Health professionals' awareness about pharmacovigilance system in Bulgaria. World Journal Of Pharmacy And Pharmaceutical Sciences 4: 1500–1513.
- Benisheva-Dimitrova T, Trendafilova P, Sidjimova D (2012) Pharmacovigilance system in WHO and in the EU. Conference proceeings. Jubilee session – 70 years Medical College – Plovdiv – Traditions and Future, 132–136.
- BDA [Bulgarian Drug Agency] (2022) Annual reports 2019–2022. http://www.bda.bg
- BDA [Bulgarian Drug Agency] (2023) Yellow card. http://www.bda.bg/pharmacovig/yellowcard/form.htm
- Commission Implementing Regulation (EU) 2022/20 of 7 January 2022 laying down rules for the application of Regulation (EU) No 536/2014 of the European Parliament and of the Council as regards setting up the rules and procedures for the cooperation of the Member States in safety assessment of clinical trials. [Text with EEA relevanc] http://data.europa.eu/eli/reg_impl/2022/20/oj
- Cox AR, Butt TF (2012) ADR ehen the risk becomes reality for patients. Drug Safety 35(11): 977–813. https://doi.org/10.1007/BF03261985
- Directive (2001a) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. http://data.europa.eu/eli/dir/2001/83/2019-07-26 [Access 23.10.23]
- Directive (2001b) Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. http://data.europa.eu/eli/dir/2001/20/2009-08-07 [Access 23.10.23]
- European Parliament (2004) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (Text with EEA relevance) Access current version (28/01/2022) EUR-Lex – 02004R0726-20190128 – EN – EUR-Lex(europa.eu). https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:02004R0726-20190128 [online access – 23.10.23]
- European Parliament (2010a) Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use. (Official Journal L 348, 31/12/2010, p. 74–99). EUR-Lex -32010L0084 – EN – EUR-Lex (europa.eu). http://data.europa.eu/eli/dir/2010/84/oj
- European Parliament (2010b) Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products Text with EEA relevance. OJ L 348, 31.12.2010, p. 1–16. http://data.europa.eu/eli/reg/2010/1235/oj
- European Parliament (2022) Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products Text with EEA relevanceOJ L 348, 31.12.2010, p. 1–16 (Special edition in Croatian: Chapter 13 Volume 064 P. 219–234. [Current consolidated version: 01/01/2011] http://data.europa.eu/eli/reg/2010/1235/oj
- European Medicines Agency (2023) Pharmacovigilance: Overview. https://shorturl.at/bkC17
- Friese B (2011) EMA and EU Commission Topical News. Important Provisions of the New Pharmacovigilance Legislation – Part II. Pharmind 73(3): 500–502.
- Hartigan-Go K (2012) Challenges of drug risk communication in the Philippines. Drug Safety 35: 995–1004. https://doi.org/10.1007/BF03261987
- Hazell L, Shakir SA (2006) Under-reporting of adverse drug reactions: a systematic review. Drug Safety 29: 385–396. https://doi.org/10.2165/00002018-200629050-00003
- Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, Pirmohamed M (2006) Which drugs cause preventable admissions to hospitals? A systematic review. British Journal of Clinical Pharmacology 63: 136–147. https://doi.org/10.1111/j.1365-2125.2006.02698.x
- Lee LY, Kortepeter CM, Willy ME, Nourjah P (2008) Drug Risk communication to pharmacists: Assessing the impact of risk-minimization strategies on the practice of pharmacy. Journal of the American Pharmacists Association 48(4): 494–500.
- Leendertse AJ, Egberts AC, Stoker LJ, van den Bemt PM (2008) Frequency of and risk factors for Preventable medication – related hospital admissions in the Netherlands. Archives of Internal Medicine 168(17): 1890–1896. https://doi.org/10.1001/archinternmed.2008.3
- Prakash J, Sachdeva R, Shrivastava TP, Jayachandran CV, Sahu A (2012) Adverse event reporting tools and regulatory measures in India through outcome of Pharmacovigilance Programme of India. Indian Journal of Pharmacology 53(2): 143–152. https://doi.org/10.4103/ijp.ijp_901_20 [PMID: 34100398; PMCID: PMC8265409]
- Smith NA (2010) There are no safe drugs, only safe ways of using them (Voltaire). Injury Prevention 16: A280–A281. https://doi.org/10.1136/ip.2010.029215.998
- Thakare V, Patil A, Mukta J, Vivek R, Deepak L (2022) ADR: Five years analysis from a teaching hospital. Journal of Family Medicine and Primary Care 11(11): 7316–7321. https://doi.org/10.4103/jfmpc.jfmpc_1043_22 [Epub 2022 Dec 16]
- Williams D, Freely J (1999) Underreporting of adverse drug reactions: attitudes of Irish doctors. Irish Journal of Medical Science 168(4): 257–261. https://doi.org/10.1007/BF02944353
- WHO [World Health Organization] (2005) Briefing Note Safety of medicines – adverse drug reactions. https://url1.io/s/Jqbw8